Skip to main content
eScholarship
Open Access Publications from the University of California

Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway

  • Author(s): Schwarzenberg, J
  • Radu, CG
  • Benz, M
  • Fueger, B
  • Tran, AQ
  • Phelps, ME
  • Witte, ON
  • Satyamurthy, N
  • Czernin, J
  • Schiepers, C
  • et al.
Abstract

Purpose: Deoxycytidine kinase (dCK) is a rate-limiting enzyme in deoxyribonucleoside salvage, a metabolic pathway involved in the production and maintenance of a balanced pool of deoxyribonucleoside triphosphates (dNTPs) for DNA synthesis. dCK phosphorylates and therefore activates nucleoside analogs such as cytarabine, gemcitabine, decitabine, cladribine, and clofarabine that are used routinely in cancer therapy. Imaging probes that target dCK might allow stratifying patients into likely responders and nonresponders with dCK-dependent prodrugs. Here we present the biodistribution and radiation dosimetry of three fluorinated dCK substrates,18F-FAC, L-18F-FAC, and L-18F-FMAC, developed for positron emission tomography (PET) imaging of dCK activity in vivo. Methods: PET studies were performed in nine healthy human volunteers, three for each probe. After a transmission scan, the radiopharmaceutical was injected intravenously and three sequential emission scans acquired from the base of the skull to mid-thigh. Regions of interest encompassing visible organs were drawn on the first PET scan and copied to the subsequent scans. Activity in target organs was determined and absorbed dose estimated with OLINDA/EXM. The standardized uptake value was calculated for various organs at different times. Results: Renal excretion was common to all three probes. Bone marrow had higher uptake for L-18F-FAC and L-18F-FMAC than18F-FAC. Prominent liver uptake was seen in L-18F-FMAC and L-18F-FAC, whereas splenic activity was highest for18F-FAC. Muscle uptake was also highest for18F-FAC. The critical organ was the bladder wall for all three probes. The effective dose was 0.00524, 0.00755, and 0.00910 mSv/MBq for18F-FAC, L-18F-FAC, and L-18F-FMAC, respectively. Conclusion: The biodistribution of18F-FAC, L-18F-FAC, and L-18F-FMAC in humans reveals similarities and differences. Differences may be explained by different probe affinities for nucleoside transporters, dCK, and catabolic enzymes such as cytidine deaminase (CDA). Dosimetry demonstrates that all three probes can be used safely to image the deoxyribonucleoside salvage pathway in humans. © 2010 The Author(s).

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View